HEXO Competitors

HEXO (TSE:HEXO) and Leaf Mobile (TSE:LEAF) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership and earnings.

Analyst Recommendations

This is a breakdown of recent recommendations for HEXO and Leaf Mobile, as provided by MarketBeat.

HEXO currently has a consensus price target of C$1.76, indicating a potential downside of 76.41%. Leaf Mobile has a consensus price target of C$0.75, indicating a potential upside of 108.33%. Given Leaf Mobile's stronger consensus rating and higher probable upside, analysts plainly believe Leaf Mobile is more favorable than HEXO.

Valuation and Earnings

This table compares HEXO and Leaf Mobile's top-line revenue, earnings per share (EPS) and valuation.

Leaf Mobile has lower revenue, but higher earnings than HEXO. Leaf Mobile is trading at a lower price-to-earnings ratio than HEXO, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares HEXO and Leaf Mobile's net margins, return on equity and return on assets.

Summary

Leaf Mobile beats HEXO on 6 of the 9 factors compared between the two stocks.

Aurora Cannabis (TSE:ACB) and HEXO (TSE:HEXO) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, institutional ownership, risk, valuation and dividends.

Earnings and Valuation

This table compares Aurora Cannabis and HEXO's revenue, earnings per share and valuation.

HEXO has lower revenue, but higher earnings than Aurora Cannabis. HEXO is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Aurora Cannabis and HEXO's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of current recommendations and price targets for Aurora Cannabis and HEXO, as provided by MarketBeat.com.

Aurora Cannabis presently has a consensus price target of C$11.91, indicating a potential upside of 16.35%. HEXO has a consensus price target of C$1.76, indicating a potential downside of 76.41%. Given Aurora Cannabis' higher possible upside, analysts plainly believe Aurora Cannabis is more favorable than HEXO.

Summary

HEXO beats Aurora Cannabis on 5 of the 8 factors compared between the two stocks.

HEXO (TSE:HEXO) and OrganiGram (TSE:OGI) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, profitability, earnings, dividends and valuation.

Profitability

This table compares HEXO and OrganiGram's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent ratings and price targets for HEXO and OrganiGram, as reported by MarketBeat.com.

HEXO currently has a consensus target price of C$1.76, indicating a potential downside of 76.41%. OrganiGram has a consensus target price of C$4.13, indicating a potential upside of 18.77%. Given OrganiGram's higher possible upside, analysts clearly believe OrganiGram is more favorable than HEXO.

Earnings and Valuation

This table compares HEXO and OrganiGram's top-line revenue, earnings per share and valuation.

HEXO has higher revenue and earnings than OrganiGram. OrganiGram is trading at a lower price-to-earnings ratio than HEXO, indicating that it is currently the more affordable of the two stocks.

Summary

HEXO beats OrganiGram on 5 of the 9 factors compared between the two stocks.

Knight Therapeutics (TSE:GUD) and HEXO (TSE:HEXO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, institutional ownership, valuation, profitability, analyst recommendations, earnings and dividends.

Earnings & Valuation

This table compares Knight Therapeutics and HEXO's gross revenue, earnings per share and valuation.

Knight Therapeutics has higher revenue and earnings than HEXO. HEXO is trading at a lower price-to-earnings ratio than Knight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Knight Therapeutics and HEXO, as reported by MarketBeat.

Knight Therapeutics currently has a consensus target price of C$7.42, indicating a potential upside of 40.73%. HEXO has a consensus target price of C$1.76, indicating a potential downside of 76.41%. Given Knight Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Knight Therapeutics is more favorable than HEXO.

Profitability

This table compares Knight Therapeutics and HEXO's net margins, return on equity and return on assets.

Summary

Knight Therapeutics beats HEXO on 7 of the 9 factors compared between the two stocks.

HLS Therapeutics (TSE:HLS) and HEXO (TSE:HEXO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.

Profitability

This table compares HLS Therapeutics and HEXO's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares HLS Therapeutics and HEXO's top-line revenue, earnings per share (EPS) and valuation.

HLS Therapeutics has higher earnings, but lower revenue than HEXO. HLS Therapeutics is trading at a lower price-to-earnings ratio than HEXO, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations for HLS Therapeutics and HEXO, as reported by MarketBeat.com.

HLS Therapeutics currently has a consensus price target of C$30.50, suggesting a potential upside of 61.29%. HEXO has a consensus price target of C$1.76, suggesting a potential downside of 76.41%. Given HLS Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe HLS Therapeutics is more favorable than HEXO.

Summary

HLS Therapeutics beats HEXO on 6 of the 8 factors compared between the two stocks.

HEXO (TSE:HEXO) and The Supreme Cannabis (TSE:FIRE) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

Analyst Ratings

This is a breakdown of current ratings for HEXO and The Supreme Cannabis, as reported by MarketBeat.

HEXO currently has a consensus price target of C$1.76, suggesting a potential downside of 76.41%. The Supreme Cannabis has a consensus price target of C$0.35, suggesting a potential downside of 9.09%. Given The Supreme Cannabis' higher probable upside, analysts plainly believe The Supreme Cannabis is more favorable than HEXO.

Profitability

This table compares HEXO and The Supreme Cannabis' net margins, return on equity and return on assets.

Valuation and Earnings

This table compares HEXO and The Supreme Cannabis' top-line revenue, earnings per share (EPS) and valuation.

The Supreme Cannabis has lower revenue, but higher earnings than HEXO. HEXO is trading at a lower price-to-earnings ratio than The Supreme Cannabis, indicating that it is currently the more affordable of the two stocks.

Summary

The Supreme Cannabis beats HEXO on 4 of the 7 factors compared between the two stocks.